Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.38 |
| ▸ | USP1 | O94782 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371718 | 0.88 | POLB (0.41) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL12371788 | 0.87 | POLB (0.44) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL12371799 | 0.85 | SMN1; SMN2 (0.43) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL12371675 | 0.85 | BRD4 (0.43) | BRD4HSD17B13USP1DPP4 | |
| SCHEMBL13620514 | 0.84 | BRD4 (0.43) | BRD4HSD17B13USP1DPP4 | |
| SCHEMBL13620265 | 0.83 | POLB (0.44) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL13608435 | 0.82 | FGFR1 (0.45) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL13620073 | 0.81 | BRD4 (0.45) | BRD4HSD17B13USP1DPP4 | |
| SCHEMBL13620415 | 0.80 | HRH4 (0.45) | BRD4TSHRHSD17B13USP1 | |
| SCHEMBL13620430 | 0.80 | QPCT (0.43) | POLBALOX15TSHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | POLB 821/4885BRD4 1920/4885ALOX15 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.